Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator A Systematic Review and Meta-Analysis of 55 Studies

被引:254
|
作者
Whiteley, William N. [1 ]
Slot, Karsten Bruins [2 ]
Fernandes, Peter [1 ]
Sandercock, Peter [1 ]
Wardlaw, Joanna [1 ,3 ]
机构
[1] Univ Edinburgh, Div Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland
[2] Oslo Univ Hosp Ulleval, Oslo, Norway
[3] Scottish Imaging Network, Edinburgh, Midlothian, Scotland
基金
英国医学研究理事会;
关键词
acute stroke; meta-analysis; systematic review; thrombolysis; THROMBOLYTIC THERAPY; INTRAVENOUS THROMBOLYSIS; SAFE IMPLEMENTATION; ALTEPLASE; MANAGEMENT; OUTCOMES; ECASS; TRIAL; SCORE;
D O I
10.1161/STROKEAHA.112.665331
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Recombinant tissue plasminogen activator (rtPA) is an effective treatment for acute ischemic stroke but is associated with an increased risk of intracranial hemorrhage (ICH). We sought to identify the risk factors for ICH with a systematic review of the published literature. Methods-We searched for studies of rtPA-treated stroke patients that reported an association between a variable measured before rtPA infusion and clinically important ICH (parenchymal ICH or ICH associated with clinical deterioration). We calculated associations between baseline variables and ICH with random-effect meta-analyses. Results-We identified 55 studies that measured 43 baseline variables in 65 264 acute ischemic stroke patients. Post-rtPA ICH was associated with higher age (odds ratio, 1.03 per year; 95% confidence interval, 1.01-1.04), higher stroke severity (odds ratio, 1.08 per National Institutes of Health Stroke Scale point; 95% confidence interval, 1.06-1.11), and higher glucose (odds ratio, 1.10 per mmol/L; 95% confidence interval, 1.05-1.14). There was approximately a doubling of the odds of ICH with the presence of atrial fibrillation, congestive heart failure, renal impairment, previous antiplatelet agents, leukoaraiosis, and a visible acute cerebral ischemic lesion on pretreatment brain imaging. Little of the variation in the sizes of the associations among different studies was explained by the source of the cohort, definition of ICH, or degree of adjustment for confounding variables. Conclusions-Individual baseline variables were modestly associated with post-rtPA ICH. Prediction of post-rtPA ICH therefore is likely to be difficult if based on single clinical or imaging factors alone. These observational data do not provide a reliable method for the individualization of treatment according to predicted ICH risk. (Stroke. 2012; 43: 2904-2909.)
引用
收藏
页码:2904 / U235
页数:25
相关论文
共 50 条
  • [1] Incidence of seizure in stroke patients treated with recombinant tissue plasminogen activator: A systematic review and meta-analysis
    Lekoubou, Alain
    Awoumou, Jean Joel
    Kengne, Andre Pascal
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2017, 12 (09) : 923 - 931
  • [2] Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
    Wardlaw, Joanna M.
    Murray, Veronica
    Berge, Eivind
    del Zoppo, Gregory
    Sandercock, Peter
    Lindley, Richard L.
    Cohen, Geoff
    [J]. LANCET, 2012, 379 (9834): : 2364 - 2372
  • [3] Risk Score for Intracranial Hemorrhage in Patients With Acute Ischemic Stroke Treated With Intravenous Tissue-Type Plasminogen Activator
    Menon, Bijoy K.
    Saver, Jeffrey L.
    Prabhakaran, Shyam
    Reeves, Mathew
    Liang, Li
    Olson, DaiWai M.
    Peterson, Eric D.
    Hernandez, Adrian F.
    Fonarow, Gregg C.
    Schwamm, Lee H.
    Smith, Eric E.
    [J]. STROKE, 2012, 43 (09) : 2293 - +
  • [4] Risk of Hemorrhage in patients on Coumadin who are treated with Tissue Plasminogen Activator for Acute Ischemic Stroke
    Sarraj, Amrou
    Medrek, Sarah K.
    Rhodes, Jeffrey
    Garza, Alexandra
    Pruit, John F.
    Martinez, Rebecca E.
    Harun, Nusrat
    Sline, Melvin R.
    Pandurengan, Renganayaki
    Lopez, George
    Barreto, Andrew
    Gonzales, Nicole R.
    Grotta, James C.
    Savitz, Sean
    [J]. STROKE, 2011, 42 (03) : E166 - E166
  • [5] Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous recombinant tissue plasminogen activator: a systematic review and meta-analysis
    Guo, Yijia
    Yang, Yaqiong
    Zhou, Muke
    He, Li
    [J]. STROKE AND VASCULAR NEUROLOGY, 2018, 3 (04) : 203 - 208
  • [6] Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
    Cheng, Ji-Wei
    Zhang, Xiao-Jing
    Cheng, Li-Shan
    Li, Guo-Yi
    Zhang, Li-Jun
    Ji, Kang-Xiang
    Zhao, Qing
    Bai, Yu
    [J]. JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2018, 27 (02): : 381 - 390
  • [7] Risk Factors Associated with Outcomes of Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Ischemic Stroke
    Tseng, Yi-Ju
    Hu, Ru-Fang
    Lee, Shin-Tyng
    Lin, Yu-Li
    Hsu, Chien-Lung
    Lin, Shih-Wei
    Liou, Chia-Wei
    Lee, Jiann-Der
    Peng, Tsung-I
    Lee, Tsong-Hai
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (02)
  • [8] Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator
    Xian, Ying
    Liang, Li
    Smith, Eric E.
    Schwamm, Lee H.
    Reeves, Mathew J.
    Olson, DaiWai M.
    Hernandez, Adrian F.
    Fonarow, Gregg C.
    Peterson, Eric D.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (24): : 2600 - 2608
  • [9] Risk factors for intracerebral hemorrhage after treatment with recombinant tissue-type plasminogen activator for acute ischemic stroke
    Phuttharak, Warinthorn
    Sawanyawisuth, Kittisak
    Sangpetngam, Boonrerk
    Tiamkao, Somsak
    Kongbunkiat, Kannikar
    Chotmongkol, Verajit
    Limpawattana, Panita
    Thongkrau, Theerayut
    Keeratikasikorn, Chaiyapon
    [J]. ASIAN BIOMEDICINE, 2015, 9 (03) : 397 - 400
  • [10] Acute Ischemic Stroke in Term Pregnancy Treated with Recombinant Tissue Plasminogen Activator
    Aaron, Sanjith
    Mannam, Pavitra Ratna
    Shaikh, Atif
    Mani, Arun Mathai
    Bal, Deepti
    Pandian, Jeyaraj Durai
    [J]. CASE REPORTS IN NEUROLOGY, 2020, 12 (SUPPL 1) : 4 - 8